FDA clears Medtronics new left-heart leads
The FDA has approved Medtronic’s Attain Ability Plus and the Attain Ability Straight left-heart leads for use with cardiac resynchronization therapy (CRT) devices in treating heart failure patients.

The two new dual-electrode leads are the latest offering in a line of left-heart lead options that fit through the Attain Select II sub-selection catheter delivery system and navigate patient vein anatomies during the CRT implant procedure, according to the Minneapolis-based company.

The product is immediately available in the U.S.